Intelligence Profile
Science
Mechanism of Action
The scientific evidence on the mechanism of action for NAD+ IV infusions is limited, with only a few studies directly examining intravenous NAD+ administration in humans.
Proposed Cellular Mechanisms:
NAD+ (nicotinamide adenine dinucleotide) is a critical coenzyme involved in cellular energy metabolism and various enzymatic reactions. The proposed mechanism suggests that direct IV infusion bypasses normal cellular uptake limitations to increase intracellular NAD+ levels.
Limited Clinical Evidence:
One pilot study (PMID: 31572171) examined changes in plasma and urine NAD+ metabolites during a 6-hour intravenous NAD+ infusion in humans. This study provides the most direct evidence of how IV NAD+ affects the body's NAD+ metabolome, though specific mechanistic details are not detailed in the available abstracts.
A retrospective tolerability study (PMID: 41704678) compared intravenous NAD+ infusions to nicotinamide riboside supplementation in real-world clinical settings, but mechanistic insights are not apparent from the available information.
Related Precursor Research:
While not directly about IV NAD+, research on NAD+ precursors provides some mechanistic context. One study (PMID: 34948019) showed that nicotinamide mononucleotide (NMN), an NAD+ precursor, prevented glucose intolerance by decreasing insulin clearance, suggesting NAD+ metabolism influences metabolic pathways.
Evidence Limitations:
The current evidence base is notably thin regarding the specific molecular and physiological mechanisms of IV NAD+ infusion. Most available research focuses on oral NAD+ precursors rather than direct intravenous administration, and the clinical trials listed do not appear to directly investigate NAD+ infusion mechanisms.
This information is for educational purposes only and should not be considered medical advice. Consult with a healthcare provider before considering any NAD+ infusion therapy.